Results 171 to 180 of about 126,141 (353)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis [PDF]

, 2018
A.M. Overstreet, Diana Latorre, Lisa Abernathy‐Close, Stephen F. Murphy, Lesley Rhee, Antonia Boger, Katie R. Adlaka, Ann Iverson, Danika Bakke, Christopher R. Weber, David L. Boone   +10 more
openalex   +1 more source

Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases

, 2023
Maximilien Murone, Anne Vaslin Chessex, Antoine Attinger, Raghuveer Ramachandra, Shankar J. Shetty, Girish Daginakatte, Saumitra Sengupta, Sivapriya Marappan, Samiulla Dhodheri, Stefania Rigotti, Yogeshwar Bachhav, S. Brienza, Peter Traxler, Marc Lang, Michel Aguet, Vincent Zoete, Olivier Michielin, Courtney Nicholas, Faye M. Johnson, Murali Ramachandra, Andrés McAllister   +20 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

, 2021
Benjamin Klein, Regina Treudler, Jan C. Simon   +2 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors [PDF]

, 2019
Anja Meyer, Paula S. Wittekind, Konstantin Kotschenreuther, Joanna Schiller, Julia von Tresckow, Thomas H. Haak, David M. Kofler   +6 more
openalex   +1 more source

JAK inhibitors boost bone formation [PDF]

Nature Reviews Rheumatology, 2020
openaire   +2 more sources

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Physalin A alleviates inflammation and oxidative stress in mouse infantile pneumonia by inhibiting JAK/STAT3 and NF κB pathways

, 2022
Zhenhua Ling, Jinhua Zhao
openalex   +1 more source

Author Correction: Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors [PDF]

, 2023
Aditi S. Bapat, Christine H. O’Connor, Kathryn L. Schwertfeger   +2 more
openalex   +1 more source